Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti-CSPG4 vaccination: A retrospective study on 68 cases (2010-2020).
anti-CSPG4 electrovaccination
bone invasion
dog
oral melanoma
prognosis
surgery
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
17
05
2021
received:
19
07
2021
accepted:
12
08
2021
pubmed:
16
8
2021
medline:
1
4
2022
entrez:
15
8
2021
Statut:
ppublish
Résumé
Prognosis of canine oral malignant melanoma encompasses clinical, histological and immunohistochemical parameters. The aim of this study was to evaluate the prognostic impact of bone invasion in oral canine melanoma. Sixty-eight dogs bearing oral melanoma staged II and III that underwent surgery and anti-CSPG4 electrovaccination, with available histological data and a minimum follow up of minimum 1 year, were retrospectively selected. Bone invasion was detected on imaging and/or histology. Median survival time of dogs with evidence of bone invasion (group 1) was 397 days and significantly shorter compared with dogs with oral melanomas not invading the bone (group 2, 1063 days). Dogs with tumours localised at the level of the cheek, lip, tongue and soft palate (soft tissue - group 3) lived significantly longer compared with dogs having tumours within the gingiva of the maxilla or mandible (hard tissue - group 4) with a median survival time of 1063 and 470 days, respectively. Within group 4, the subgroup of dogs with tumours not invading the bone (group 5) showed a significant prolonged survival time (972 days) in comparison with dogs of group 1 (bone invasion group). Similar results were obtained for the disease-free intervals amongst the different groups. Statistical analysis showed that Ki67 and mitotic count were correlated with shorter survival in patients of group 1 (with bone invasion). Bone invasion should always be assessed since it appears to be a negative prognostic factor.
Identifiants
pubmed: 34392602
doi: 10.1111/vco.12761
pmc: PMC9290081
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
189-197Informations de copyright
© 2021 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.
Références
J Vet Med Sci. 2016 Jun 1;78(5):845-50
pubmed: 26781703
Am J Vet Res. 2011 Dec;72(12):1631-8
pubmed: 22126691
J Am Vet Med Assoc. 2014 Dec 1;245(11):1266-73
pubmed: 25406707
Vet Comp Oncol. 2016 Dec;14(4):e146-e157
pubmed: 25382434
J Cell Biol. 2004 Jun 21;165(6):881-91
pubmed: 15210734
Vet J. 2011 Nov;190(2):e26-e30
pubmed: 21482159
Vet Surg. 2018 Jul;47(5):629-633
pubmed: 30129062
Vet Pathol. 2006 Mar;43(2):136-49
pubmed: 16537931
Vet Pathol. 2017 Jul;54(4):579-587
pubmed: 28346126
J Am Vet Med Assoc. 2003 May 1;222(9):1234-6
pubmed: 12725311
Vet Sci. 2016 Feb 19;3(1):
pubmed: 29056717
Vet Comp Oncol. 2017 Jun;15(2):462-469
pubmed: 26833575
J Am Vet Med Assoc. 2015 Nov 15;247(10):1146-53
pubmed: 26517618
Pigment Cell Melanoma Res. 2011 Dec;24(6):1148-57
pubmed: 22004131
Clin Cancer Res. 2003 Apr;9(4):1284-90
pubmed: 12684396
J Am Vet Med Assoc. 2004 Feb 1;224(3):388-94
pubmed: 14765798
J Vet Dent. 2013 Summer;30(2):72-6
pubmed: 24006715
Front Vet Sci. 2020 Sep 29;7:575911
pubmed: 33134356
Vet Surg. 1991 Nov-Dec;20(6):397-401
pubmed: 1369522
Vet Radiol Ultrasound. 2020 Jul;61(4):471-480
pubmed: 32323424
Vet Comp Oncol. 2013 Sep;11(3):219-29
pubmed: 23909996
J Am Vet Med Assoc. 2001 May 1;218(9):1444-8
pubmed: 11345308
Vet Comp Oncol. 2017 Mar;15(1):208-214
pubmed: 26040551
Vet Comp Oncol. 2017 Sep;15(3):881-889
pubmed: 27196324
Vet Dermatol. 2006 Apr;17(2):141-6
pubmed: 16515657
J Am Vet Med Assoc. 2010 Feb 1;236(3):319-25
pubmed: 20113245
Vet Comp Oncol. 2021 Dec;19(4):651-660
pubmed: 33751759
Vet Comp Oncol. 2018 Dec;16(4):562-570
pubmed: 29989306
Cancer Immunol Immunother. 2019 Nov;68(11):1839-1853
pubmed: 31222484
J S Afr Vet Assoc. 2015 Apr 30;86(1):1246
pubmed: 26016668
Vet Comp Oncol. 2014 Mar;12(1):78-84
pubmed: 22737988
Vet Comp Oncol. 2022 Mar;20(1):189-197
pubmed: 34392602
Vet Comp Oncol. 2021 Jun;19(2):353-361
pubmed: 33443307
J Transl Med. 2017 Jul 1;15(1):151
pubmed: 28668095
Res Vet Sci. 2019 Feb;122:40-49
pubmed: 30453179
Clin Tech Small Anim Pract. 2007 May;22(2):55-60
pubmed: 17591290
Crit Rev Immunol. 2004;24(4):267-96
pubmed: 15588226
J Am Vet Med Assoc. 2019 Apr 15;254(8):938-943
pubmed: 30938614
Clin Cancer Res. 2014 Jul 15;20(14):3753-62
pubmed: 24874834
J Vet Intern Med. 2003 Jan-Feb;17(1):96-101
pubmed: 12564733
Vet Pathol. 2011 Jan;48(1):54-72
pubmed: 21266721
J Am Vet Med Assoc. 2014 Aug 15;245(4):401-7
pubmed: 25075823
Vet Pathol. 2011 Jan;48(1):19-31
pubmed: 21123864
N Z Vet J. 2013 Jan;61(1):25-31
pubmed: 22913610
Radiol Oncol. 2020 Mar 7;54(1):68-78
pubmed: 32187017
Vet Comp Oncol. 2014 Dec;12(4):310-8
pubmed: 23095099
Vet Pathol. 2011 Jan;48(1):41-53
pubmed: 21123859
Vet Comp Oncol. 2005 Dec;3(4):222-9
pubmed: 19754777
Vet Comp Oncol. 2017 Sep;15(3):996-1013
pubmed: 27146852
Vaccine. 2006 May 22;24(21):4582-5
pubmed: 16188351
Vet Radiol Ultrasound. 2003 May-Jun;44(3):352-9
pubmed: 12816381
Vet Surg. 1992 Sep-Oct;21(5):337-41
pubmed: 1413465